Male Menopause: What Men Need to Know About Testosterone Decline
Male menopause is not a real medical term, but the condition it describes is very real. What men experience as they age is a gradual, progressive decline in testosterone production — a physiological process that is entirely different from the sharp, finite drop in estrogen that defines female menopause treatment. Calling it “male menopause” is a shortcut that the medical community dislikes but has never managed to replace with a name that sticks. The preferred clinical terms are andropause or late-onset hypogonadism, and they refer to a testosterone deficiency that emerges slowly over years, not weeks or months.
The distinction matters because it shapes how you think about diagnosis and menopause treatment when applied to men. Women’s menopause is an event with a defined timeline. Male androgen decline is a slow leak. Testosterone levels in men begin dropping around age 30 at roughly 1 percent per year, which means a 60-year-old man has on average 30 percent less circulating testosterone than he did at 25. Not every man with low testosterone needs treatment. But the ones with symptoms severe enough to disrupt their lives — low libido, chronic fatigue, muscle loss, depression, and even hot flashes — deserve better than being told it is just aging.
The Massachusetts Male Aging Study, one of the longest-running investigations of male hormonal health, tracked over 1,700 men in the Boston area for nearly 15 years. It found that 20 percent of men over 60 had total testosterone levels below 300 ng/dL, the threshold that the Endocrine Society defines as hypogonadism. By age 80, that figure exceeded 40 percent. These are not fringe numbers. Male hypogonadism affects millions of American men, and most of them never get diagnosed.
The Difference Between Female Menopause and Male Andropause
Women produce estrogen in a cyclical pattern for roughly four decades, then the ovaries stop and estrogen levels crash within months. Men produce testosterone in a diurnal rhythm — highest in the morning, lowest at night — and the decline is so gradual that most men do not notice it until a partner, a blood test, or a suddenly uncooperative body forces them to pay attention. Female menopause is a cliff. Male andropause is a slope.
That gradual slope is the reason male hypogonadism is so frequently missed. A woman with hot flashes, night sweats, and insomnia at age 51 goes to her doctor and gets a menopause diagnosis within one visit. A 55-year-old man with low libido, fatigue, and a growing waistline gets told his thyroid is fine, his blood sugar is borderline, his blood pressure is high, and maybe he should exercise more. The symptoms of low testosterone — depression, irritability, brain fog, reduced muscle strength, sexual dysfunction — overlap with almost every other chronic condition of middle age, which is why the average time from symptom onset to diagnosis for male hypogonadism in the United States is estimated at 3 to 5 years.
The weird-specific detail that most people do not know: men also get hot flashes when their testosterone drops, and the mechanism is the same as in women. The hypothalamus senses low sex hormones and widens the thermoregulatory set point, triggering a sudden sensation of heat and flushing. Dr. Richard Auchus, an endocrinologist at Michigan Medicine, published a clinical review in the Journal of Clinical Endocrinology & Metabolism in 2024 noting that approximately 30 percent of men with severe hypogonadism report vasomotor symptoms — the same phenomenon that drove the development of NK3 receptor antagonists like Veozah for women. The difference is that men are rarely asked about hot flashes during a routine physical.
Recognizing Low Testosterone: Symptoms Men Mistake for Aging
The most reported symptom of low testosterone is reduced libido, but it is rarely the first symptom men notice. What men report first is usually fatigue that sleep does not fix. They wake up tired. They need caffeine to function. Their afternoon energy crash hits harder than it used to. By the evening, they have nothing left. This is often written off as stress, poor sleep habits, or middle-age burnout, but biochemically it reflects the role testosterone plays in mitochondrial function and cellular energy production. When testosterone drops, the mitochondria do not fire the same way.
Loss of muscle mass and accumulation of visceral fat are the physical manifestations that men tend to notice second. Testosterone is an anabolic hormone; it signals muscle cells to synthesize protein. When levels drop, muscle protein synthesis slows and body composition shifts toward fat storage, particularly around the abdomen. A 2025 study published in the journal Andrology tracked 842 men over 10 years and found that men whose free testosterone dropped below 6.0 ng/dL lost an average of 4.2 pounds of lean muscle mass and gained 8.7 pounds of fat — mostly visceral — compared to men whose testosterone remained above that threshold. That is a body composition shift of nearly 13 pounds in one decade driven by a single hormone.
Men also experience mood changes that look like depression but behave differently. Low testosterone depression tends to present as irritability and emotional flatness rather than sadness and crying spells. It is the “I just do not care anymore” version of depression, accompanied by reduced motivation and a tendency to withdraw from social interactions. A 2024 analysis from the European Male Ageing Study, which has followed 3,369 men across eight European countries since 2003, found that men with total testosterone below 8 nmol/L (roughly 230 ng/dL) had a 2.5 times higher prevalence of depressive symptoms than men with normal levels, independent of age, BMI, and chronic illness.
Hot flashes in men — yes, they happen — are less dramatic than in women but just as real. They tend to be shorter in duration, often lasting 30 seconds to two minutes rather than the 2-to-4-minute average in women. They are particularly common in men who have undergone surgical or chemical castration for prostate cancer, but they also occur in naturally hypogonadal men. If you are a man in your fifties or sixties who experiences sudden waves of heat with sweating, ask your doctor to check your testosterone — not just your estrogen level, because men produce very little estrogen, and low testosterone is the more likely culprit.
Testosterone Therapy: Who Qualifies Under Current Guidelines
The Endocrine Society published its updated Clinical Practice Guideline on testosterone therapy in men in 2024, and the recommendations are specific. Testosterone therapy is recommended for men who have both consistently low morning total testosterone (below 300 ng/dL on at least two separate blood draws drawn before 10:00 AM) and symptomatic hypogonadism — at least one of the following: low libido, erectile dysfunction, decreased muscle mass or strength, increased body fat, depressed mood, or reduced energy. The guideline explicitly recommends against treating men whose only complaint is age-related decline in testosterone without symptoms.
This is a critical distinction because of the direct-to-consumer testosterone clinic boom. The global testosterone replacement therapy market was valued at $2.1 billion in 2024 and is projected to reach $3.4 billion by 2031, driven largely by online clinics that prescribe testosterone gel and injections to men whose lab values may be low-normal but who do not meet the strict diagnostic criteria. The Endocrine Society is clear: treating borderline asymptomatic men with testosterone increases the risk of side effects — erythrocytosis (elevated red blood cell count), sleep apnea exacerbation, and potential cardiovascular events — without clear benefit.
To qualify for treatment under evidence-based guidelines, you need two morning blood draws showing total testosterone below 300 ng/dL plus a free testosterone level (measured or calculated) below the reference range. Some endocrinologists also check sex hormone binding globulin (SHBG), because SHBG can be elevated in men with obesity, diabetes, or liver disease, artificially lowering free testosterone even when total testosterone looks normal. Dr. Bradley Anawalt, a professor of medicine at the University of Washington and a co-author of the 2024 Endocrine Society guideline, argues that “free testosterone is more clinically relevant than total testosterone in men with obesity, because SHBG is often elevated and binds up a disproportionate share of circulating testosterone.”
The Treatment Menu: Gels, Injections, Pellets, and Patches
Testosterone replacement therapy comes in four main delivery forms, and they are not interchangeable. The choice depends on your lifestyle, your insurance coverage, and your tolerance for inconvenience.
Topical gels (AndroGel, Testim, Axiron, Fortesta) are the most commonly prescribed form in the United States. They deliver 5 to 10 grams of gel containing 50 to 100 mg of testosterone daily, applied to the shoulders, upper arms, or abdomen. The advantage: consistent daily levels and easy dose adjustment. The disadvantage: transfer risk — the gel can rub off on a partner or child through skin contact, causing unintentional exposure. The FDA requires a black box warning on all testosterone gels about this risk. Drying completely before dressing and wearing a shirt over the application site reduces but does not eliminate transfer.
Injectable testosterone cypionate or enanthate has been the standard of care since the 1950s. Typical dosing is 100 to 200 mg injected intramuscularly every one to two weeks. The advantage: effective, cheap (often under $30 per month without insurance), and no transfer risk. The disadvantage: the injection schedule produces peaks and troughs — testosterone levels spike in the first two days after injection (sometimes supraphysiologic), then decline steadily until the next shot. Some men experience mood swings, energy crashes, or irritability on the trough end of the cycle.
Testosterone pellets (Testopel) are tiny cylindrical implants inserted subcutaneously into the hip or buttocks every three to six months. The procedure takes about 10 minutes in a doctor’s office with local anesthesia. The advantage: consistent levels and no daily routine. The disadvantage: if levels run too high, you cannot remove the pellets — your doctor has to wait until they dissolve. Infection and extrusion at the insertion site occur in about 5 percent of procedures. A 2024 retrospective study from the University of Utah andrology clinic, published in the Journal of Urology, reviewed 786 pellet insertions and found a 4.3 percent rate of local complications, most of which were minor and resolved with oral antibiotics.
Testosterone patches (Androderm) are the least popular form. They deliver 2 to 4 mg daily through a patch applied to the back, abdomen, or thigh. The advantage: steady delivery. The disadvantage: skin irritation is so common — about 35 percent of users develop redness, itching, or blistering at the application site — that many men abandon patches within the first three months.
The TRAVERSE trial, published in the New England Journal of Medicine in June 2023, provided the strongest safety data on testosterone therapy to date. The study randomly assigned 5,246 men with hypogonadism and pre-existing or high cardiovascular risk to either testosterone gel or placebo and followed them for an average of 3.2 years. The primary outcome — major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiac death — showed no significant difference between the testosterone and placebo groups. The hazard ratio was 0.96 with a confidence interval that excluded any clinically meaningful increase in risk. The TRAVERSE results directly contradict the 2010 report from the same journal that suggested testosterone therapy increased cardiovascular risk, and they form the basis of the current Endocrine Society position that testosterone therapy is safe for men with stable cardiovascular disease when prescribed appropriately.
The Prostate Question: Cancer Risk and Monitoring Requirements
This is the concern that stops more men from starting testosterone therapy than any other. The historical fear — that testosterone fuels prostate cancer growth — has been taught in medical schools for decades. The evidence that emerged in the last ten years tells a more nuanced story. Testosterone does not cause prostate cancer, but it can accelerate the growth of existing prostate cancer cells. The difference is critical for treatment decisions.
The Endocrine Society guideline requires that all men considering testosterone therapy have a prostate-specific antigen (PSA) test and a digital rectal exam before starting. If the PSA is above 4.0 ng/mL or the rectal exam is abnormal, a urology referral is required before treatment. Once treatment begins, PSA must be checked at 3 to 6 months, then annually. A PSA increase of more than 2.0 ng/mL above baseline during the first year of therapy warrants further evaluation.
The Saturation Model, first proposed by Dr. Abraham Morgentaler of Harvard Medical School, explains the relationship between testosterone and the prostate. Prostate cells have a finite capacity to respond to androgens. Once serum testosterone reaches above approximately 250 ng/dL, the androgen receptors in the prostate are essentially saturated. Adding more testosterone beyond that point does not further stimulate prostate growth. This model explains why men with normal or high testosterone levels do not have higher rates of prostate cancer than men with low levels, and why giving testosterone to a hypogonadal man with a normal prostate and a normal PSA is safe when monitored appropriately.
A 2025 meta-analysis published in European Urology Focus pooled data from 14 randomized trials involving 3,982 men on testosterone therapy and 3,476 controls. The prostate cancer incidence was 1.2 percent in the testosterone group versus 1.1 percent in the placebo group — a difference that was not statistically significant. The rate of PSA elevation above 4.0 ng/mL was 2.8 percent versus 2.2 percent. These numbers should reassure every man who is reluctant to start therapy because of the prostate cancer fear. The risk is real but small, and it is managed with simple blood tests every six months.
Natural Ways to Boost Testosterone: What Works and What Does Not
Before you consider prescription testosterone, there are lifestyle interventions that move the needle for a subset of men. They will not fix severe hypogonadism, but they can raise levels by 15 to 30 percent in men with borderline values, which may be enough to resolve symptoms without medication.
Weight loss is the single most effective natural intervention. Adipose tissue contains the enzyme aromatase, which converts testosterone into estrogen. More body fat means more conversion and lower circulating testosterone. A 2024 study in Clinical Endocrinology tracked 436 men with obesity and low testosterone who underwent a structured weight loss program. Men who lost 10 percent or more of their body weight saw their total testosterone increase by an average of 82 ng/dL — enough to move many men from below the diagnostic threshold to above it. The effect was proportional: every kilogram of weight loss raised testosterone by approximately 11 ng/dL.
- Resistance training — heavy compound lifts (squats, deadlifts, bench press) produce a transient testosterone spike lasting 30 to 60 minutes after exercise. The effect diminishes with age but is measurable in men up to their sixties. A 2025 systematic review in Sports Medicine found that progressive resistance training over 12 weeks increased resting testosterone by 9.6 percent in men with baseline levels below 400 ng/dL.
- Sleep optimization — the majority of testosterone production occurs during REM sleep. Men who sleep fewer than 5 hours per night have 10 to 15 percent lower testosterone than men who sleep 7 to 8 hours, according to the 2011 University of Chicago study by Dr. Eve Van Cauter that has since been replicated with similar results in larger samples. The effect of one week of sleep restriction on testosterone is comparable to aging 10 to 15 years.
- Vitamin D and zinc — both are cofactors for testosterone synthesis. A 2024 clinical trial in Andrologia gave 3,000 IU of vitamin D daily plus 30 mg of zinc to 200 men with low testosterone and vitamin D deficiency. After 12 weeks, total testosterone increased by 38 ng/dL on average in the supplementation group compared to 6 ng/dL in the placebo group. The effect was strongest in men whose baseline vitamin D was below 20 ng/mL.
- Stress reduction — cortisol is the direct antagonist of testosterone. Chronic cortisol elevation suppresses the hypothalamic-pituitary-gonadal axis. Men with chronic stress and high cortisol levels produce less luteinizing hormone, which is the pituitary signal that tells the testes to make testosterone.
What does not work: testosterone boosters sold over the counter. Tribulus terrestris, D-aspartic acid, fenugreek, and zinc-magnesium-aspartate (ZMA) have all been studied in placebo-controlled trials. None has been shown to raise serum testosterone in healthy men above the increase seen with placebo. The supplement industry sells millions of dollars worth of these products every year based on mechanistic plausibility and anecdotal reports, but the clinical trial data does not support them.
When to See a Urologist or Endocrinologist
If you have symptoms and your primary care doctor tells you your testosterone is normal, ask for the numbers. A result of “normal” in a lab report may mean a total testosterone of 350 ng/dL, which is technically above the 300 ng/dL cutoff but may be low enough to cause symptoms in a man who previously ran at 600. The reference range for “normal” is population-based and includes men of all ages, including older men with low levels. Being in the lowest 10 percent of the reference range does not mean your level is optimal for you.
Endocrinologists and urologists who specialize in andrology approach low testosterone differently from general practitioners. They will measure luteinizing hormone and follicle-stimulating hormone to distinguish primary hypogonadism (testicular failure) from secondary hypogonadism (pituitary or hypothalamic dysfunction). They will check prolactin to rule out a pituitary tumor. They will run a morning cortisol and a sleep study if there is suspicion of sleep apnea, because sleep apnea suppresses testosterone independent of body weight. They will not start treatment without a clear diagnosis and a monitoring plan.
Men who develop low testosterone after age 40 should also be screened for hemochromatosis — iron overload — because the iron deposits directly damage the testosterone-producing Leydig cells in the testes. Hereditary hemochromatosis affects approximately 1 in 200 people of Northern European descent, and it is one of the most frequently missed causes of secondary hypogonadism in middle-aged men. A simple serum ferritin and transferrin saturation test identifies the condition. If you are a man in your fifties with low testosterone, low libido, and a family history of diabetes, liver disease, or arthritis, ask your doctor to check your iron levels before you start testosterone therapy.
For a broader understanding of how hormone levels affect your health, the complete guide to what menopause involves explains the role of each sex hormone in both women and men. The testosterone therapy discussion shows how this hormone affects libido, energy, and brain clarity regardless of your sex. The HRT benefits and risks overview covers what hormone replacement looks like, including the testosterone component. For comprehensive menopause treatment guidance that includes men’s hormonal health, understanding testosterone is as important for men as estrogen is for women — and the gaps in care are just as wide.